Clinical Research Directory
Browse clinical research sites, groups, and studies.
Realizing Effectiveness Across Continents With Hydroxyurea (REACH)
Sponsor: Children's Hospital Medical Center, Cincinnati
Summary
REACH is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for for pediatric patients with sickle cell anemia (SCA). The short-term goal is to obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for children with SCA in multiple distinct research settings in Africa. Based on that information, the longer-term goal is to make hydroxyurea more widely available for children with SCA in Africa, particularly those identified with SCA through expanded newborn screening programs.
Official title: REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA
Key Details
Gender
All
Age Range
1 Year - 10 Years
Study Type
INTERVENTIONAL
Enrollment
635
Start Date
2014-06
Completion Date
2033-08
Last Updated
2025-05-14
Healthy Volunteers
No
Conditions
Interventions
Hydroxyurea
Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
Locations (4)
Hospital Pediátrico David Bernardino
Luanda, Angola
Centre Hospitalier Monkole
Kinshasa, Democratic Republic of the Congo
KEMRI/Wellcome Trust Research
Kilifi, Kenya
Ministry of Health Mbale Regional Hospital
Mbale, Uganda